Diagnoses of insomnia have been on the rise—and so has the use of medication to treat this sleep disorder. The popularity of a newer class of drugs—non-benzodiazepine sedative hypnotics—has risen dramatically. Drugs included in this group include zolpidem, zaleplon, and eszopiclone, and are sometimes referred to as “Z-meds” or “Z-drugs.” Some of the most frequently prescribed sleep medications contain these drugs, including Ambien and Ambien CR, Zolpimist, Intermezzo, Sonata and Lunesta.
There is a great deal we don’t yet know about long-term risks and complications of these newer sleep medications. We are also just beginning to get a sense of how frequently they are being used by adults in the U.S. What’s more, we know very little about the characteristics and non-sleep health and lifestyle factors that might influence a person’s likelihood to use these medicines—whether by their own prescription, or through sharing medication prescribed for someone else.
These are important questions to pursue. This information can help scientists achieve a deeper, more comprehensive understanding of the risks and effects of the drugs themselves, and help clinicians treat insomnia and other sleep disorders safely and responsibly. A recently released study has addressed some of these gaps in knowledge. Researchers at Beth Israel Deaconess Hospital, Massachusetts General Hospital, and Harvard University conducted research to determine the prevalence of medications commonly prescribed for insomnia, and to examine the patterns of sleep medication use among adults in the U.S. They also investigated whether demographic, health, and lifestyle factors might be associated with a greater likelihood of use.
Researchers used data from the National Health and Nutrition Examination Survey (NHANES), an ongoing federal research project that collects and shares data about the health status and habits of children and adults in the U.S. The study used nationally-representative information from more than 32,000 men and women age 20 and older, collected between the years 1999 and 2010. The study identified people who had used medication commonly prescribed for insomnia within the past 30 days. Researchers also extracted details about the types of medication used, characteristics including age, gender, insurance status, and income, as well as health issues among those who’d used medication for sleep in the past month. Their analysis confirms a significant increase in the use of prescription sleep meds—particularly “Z-meds”—among American adults. Their results also paint a more detailed picture than we’ve seen before of the people who are more likely to rely on prescription medications for sleep, including women, older adults, and people who’ve sought mental health treatment:
Researchers found several characteristics associated with higher rates of use of prescription aids for sleep:
These last findings are particularly troubling, indicating that among the millions of people using sleep medications, there are many who are using multiple medications at once, putting them at greater risk for complications and adverse reactions.
Another detail that jumps out? Researchers found that more than half—58.1%—of respondents who said they’d used any type of pill or medication for sleep in the past month did not report using prescription sleep medication. This suggests that for all the millions of people using prescription sleep aids, an even greater number of people are using non-prescription medicines for sleep. Research that explores the frequency and patterns of over-the-counter sleep aid use is scarce, and its time for that to change.
Similar to another recent study on sleep medication use, this current study looks only at prescription medication use in previous 30 days, so there is no way to tell how much of this usage is short-term versus long term. Most prescription sleep aids for insomnia are intended for short-term use, to break the cycle of sleeplessness and anxiety about one’s ability to fall asleep. We need to see more research that distinguishes between short-term and long-term patterns of use of these drugs.
Still, there is a great deal that’s illuminating in these findings. This study provides us with a more detailed picture than we’ve had previously about the people most likely to rely on prescription sleep aids. This gives us an opportunity to begin to assess the effectiveness of these treatments, and the risks, for these specific groups. The progress achieved here also reinforces just how much more we need to know about these drugs and their long-term effects, so that they can be used safely and appropriately.
Michael J. Breus, Ph.D.
The Sleep Doctor™